Scarica l'app Stockscreener
2.09
2.94%
0.05
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com Canada
Palisade Bio (PALI) director adds 30,000 shares in open-market buys - Stock Titan
Price to book forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Palisade Bio stock rating on FDA trial clearance - Investing.com South Africa
Enterprise value to revenue forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? - Stocktwits
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2500 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Index - marketscreener.com
Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis - marketscreener.com
Palisade Bio stock surges on FDA clearance for UC trial By Investing.com - Investing.com South Africa
Palisade Bio stock surges on FDA clearance for UC trial - Investing.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Climbs As Palisade Bio Loads Up Dealmakers - StocksToTrade
PALI Stock Grinds Higher As Pipeline And Board Upgrades Draw Trader Focus - timothysykes.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Value Benchmark - marketscreener.com
Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial - Moomoo
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Value Benchmark Index - marketscreener.com
Palisade Bio receives FDA clearance for ulcerative colitis trial By Investing.com - Investing.com South Africa
Palisade Bio receives FDA clearance for ulcerative colitis trial - Investing.com
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis - The Manila Times
Palisade Bio clears FDA hurdle for ulcerative colitis trial - Stock Titan
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 3000E Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Index - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 3000E Value Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Dynamic Index - marketscreener.com
Palisade Bio, Inc. Actuals & Estimates (FWB:7NS0) - TradingView
Palisade Bio Inc (PALI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palisade Bio, Inc. Actuals & Estimates (NASDAQ:PALI) - TradingView
PALI Forecast — Price Target — Prediction for 2027 - TradingView
Palisade Bio Inc (PALI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Director at Palisade Bio (PALI) granted 336,904 RSUs with three-year vesting - Stock Titan
Palisade Bio (PALI) director Robert Baltera Jr. files initial Form 3 - Stock Titan
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio (PALI) director Jordan Michael Zwick files baseline Form 3 - Stock Titan
Palisade Bio (PALI) director gets 592,300 RSU grant and 20,200 RSUs vest - Stock Titan
Palisade Bio (PALI) director reports major RSU grant and new share holdings - Stock Titan
Palisade Bio (PALI) director Emil Chuang reports new RSU awards - Stock Titan
Palisade Bio (PALI) Holds Steady Near Key Support After Modest GainTriple Top - lwvtexas.org
Palisade Bio, Inc. Approves Amendments to Equity Incentive and Employee Stock Purchase Plans at 2026 Annual Meeting – Minichart - Minichart
Palisade Bio (PALI) director receives 336,904 RSUs in equity grant - Stock Titan
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters - TipRanks
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Palisade Bio adds two directors with biotech expertise - Investing.com
Palisade Bio adds two directors with biotech expertise By Investing.com - Investing.com Australia
1.53%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):